APO-1/Fas gene: Structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases

Indian Journal of Human Genetics

Volumn 15, Issue 3, 2009, Pages 98-102

  Singh, Richa ^a   Pradhan, Vandana ^a   Patwardhan, Manisha ^a   Ghosh, K ^a  

^a NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

APO 1 Fas promoter; Autoimmune diseases; Systemic lupus erythematosus

Indexed keywords

CASPASE 8; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GAMMA INTERFERON RECEPTOR; PROCASPASE 8;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BEHCET DISEASE; CHROMOSOME 10; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; PROMOTER REGION; REVIEW; SILICOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

EID: 77949590816     PISSN: 09716866     EISSN: 1998362X     Source Type: Journal    
DOI: 10.4103/0971-6866.60184     Document Type: Review

References (46)

1. Lahita RG, editor. Textbook of the autoimmune diseases. Philadelphia: Lippincott Williams and Wilkins; 2000.
2. Tan EM, Chan EK, Sullivan KF, Rubin RL. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 1988;47:121-141
3. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the Apo-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-10715
4. Orlinick JR, Vaishnaw A, Elkon KB, Chao MV. Requirement of cysteine-rich repeats of the Fas receptor for binding by the Fas ligand. J Biol Chem 1997;272:28889-28894
5. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243
6. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol 1994;24:3057-3062
7. Inazawa J, Itoh N, Abe T, Nagata S. Assignment of the human Fas antigen gene (FAS) to 10q24.1. Genomics 1992;14:821-822
8. Litcher P, Walczak H, Weitz S, Behrmann I, Krammer PH. The human APO-1 (APT) antigen maps to 10q23: A region that is systenic with mouse chromosome 19. Genomics 1992;14:179-180
9. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-946
10. Cheng J, Lin C, Koopman WJ, Mountz JD. Characterization of human Fas gene: Exon/intron organization and promoter region. J Immunol 1995;154:1239-1245
11. Rudert F, Visser E, Forbes L, Lindridge E, Wang Y, Watson J. Identification of a silencer, enhancer, and basal promoter region in human CD95 (Fas/APO-1) gene. DNA Cell Biol 1995;14:931-937
12. Xia B, Yu BH, Guo QS, Li XY, Jiang L, Li J. Association of Fas-670 gene polymorphism with inflammatory bowel disease in Chinese patients. World J Gastroenterol 2005;11:415-417
13. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-582
14. Huang QR, Danis V, Lassere M, Edmonds J, Manolios N. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatol 1999;38:645-651
15. Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic lupus eythematosus. J Rheumatol 2002;29:1183-1188
16. Horiuchi T, Nishizaka H, Yasunaga S, Higuchi M, Tsukamoto H, Hayashi K, et al. Association of Fas/APO-1 gene polymorphism with systemic lupus erythematosus in Japanese. Rheumatol 1999;38:516-520
17. Huang QR, Teutsch SM, Buhler MM, Bennetts BH, Heard RN, Manolios N, et al. Evaluation of the APO-1/Fas promoter MvaI polymorphism in multiple sclerosis. Mult Scler 2000;6:14-18
18. van Veen T, Kalkers NF, Crusius JB, van Winsen L, Barkhof F, Jongen PJ, et al. The FAS-670 polymorphism influences susceptibility to multiple sclerosis. J Neuroimmunol 2002;128:95-100.
19. Hiraide A, Imazeki F, Yokosuka O, Kanda T, Kojima H, Fukai K, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol 2005;100:1322-1329
20. Liakouli V, Manetti M, Pacini A, Tolusso B, Fatini C, Toscano A, et al. The -670G . A polymorphism in the Fas gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheu Dis 2009;68:584-590
21. Bolstad AI, Wargelius A, Nakken B, Haga HJ, Jonsson R. Fas and Fas ligand gene polymorphism in primary Sjögren's Syndrome. J Rheumatol 2000;27:2397-2405
22. Mullighan CG, Heatley S, Lester S, Rischmueller M, Gordon TP, Bardy PG. Fas gene promoter polymorphisms in primary Sjögren's Syndrome. Ann Rheum Dis 2004;63:98-101.
23. Stuck BJ, Pani MA, Besrour F, Segni M, Krause M, Usadel KH, et al. No association of two Fas gene polymorphisms with Hashimoto's thyroiditis and Grave's disease. Eur J Endocrinol 2003;149:393-396
24. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional Fas promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-4330
25. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995;154:2706-2713
26. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365
27. Diecker JWC, van der Vlag J, Berden JHM. Deranged removal of apoptotic cells: Its role in the genesis of lupus. Nephrol Dial Transplant 2004;19:282-285
28. Casiola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-1330
29. Rahman A, Isenberg DA. Mechanisms of disease: Systemic lupus erythematosus. N Engl J Med 2008;358:929-939
30. Vaishnaw AK, Toubi E, Ohsako S, Drappa J, Buys S, Estrada J, et al. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. Arthritis Rheum 1999;42:1833-1842.
31. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994; 94:954-964
32. Courtney PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL. Lymphocyte apoptosis in systemic lupus erythematosus: Relationships with Fas expression, serum soluble Fas and disease activity. Lupus 1999;8:508-513
33. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W. Involvement of the CD95 (Apo-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996;184:1513-1518
34. Debatin KM, Goldman CK, Waldmann TA, Krammer PH. APO-1 induced apoptosis of leukemia cells from patients with adult t-cell leukemia. Blood 1993;81:2972-2977
35. Wasfi YS, Silveira LJ, Jonth A, Hokanson JE, Fingerlin T, Sato H, et al. Fas promoter polymorphism: Genetic predisposition to sarcoidosis in African-American. Tissue Antigen 2008;72:39-48.
36. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-1230
37. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994;19:1354-1359
38. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by soluble form of the Fas molecule. Science 1994;263:1759-1762
39. Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997;107:89-95.
40. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Levels of soluble Fas/APO-1 in patients with Behcet's disease. Mediators Inflamm 1998;7:111-114
41. Tomokuni A, Aikoh T, Matsuki T, Isozaki Y, Otsuki T, Kita S, et al. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumors. Clin Exp Immunol 1997;110:303-309
42. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in non-hematopoietic human malignancy. Cancer Res 1996;56:3870-3874
43. Anaya JM, Gomez L, Castiblanco J. Is there a common genetic basis for autoimmune diseases? Clin Dev Immunol 2006;13:185-195
44. Vyse TJ, Todd JA. Genetic analysis of autoimmune diseases. Cell 1996;85:311-318
45. Rovin BH, Birmingham DJ, Nagaraja HN, Yu CY, Hebert LA. Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis 2007;65:187-193
46. Huang Z, Shi Y, Cai B, Wang L, Wu Y, Ying B, et al. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of systemic lupus erythematosus. Rheumatology 2009;48:626-631